A Study to Evaluate the Bioavailability of BMS-986205

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-04

Study Completion Date

2018-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assess the absolute bioavailability of a tablet formulation of BMS-986205 following simultaneous oral administration of BMS-986205 and intravenous infusion of \[13C\]BMS-986205 solution for intravenous administration in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

NCT03739788

Healthy Participants

COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

NCT07226817

Healthy Volunteers

ACTIVE_NOT_RECRUITING PHASE1

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

NCT06577259

Healthy Participants

COMPLETED PHASE1

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

NCT03035734

Healthy

WITHDRAWN PHASE1

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

NCT05963932

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BMS-986205

Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of \[13C\]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration

Group Type EXPERIMENTAL

BMS-986205

Intervention Type DRUG

Specified Dose on Specified Days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BMS-986205

Specified Dose on Specified Days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive
* Must have normal renal function demonstrated by an estimated glomerular filtration rate, calculated by Chronic Kidney Disease Epidemiology Collaboration formula
* Women must not be of childbearing potential (cannot become pregnant)

Exclusion Criteria

* Women who are of childbearing potential or breastfeeding
* Any significant acute or chronic medical illness
* Active tuberculosis (TB) requiring treatment or documented latent TB at screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes